65th ASH Annual Meeting & Exposition: 627. Aggressive Lymphomas: Clinical and Epidemiological: Treatment to Best Outcomes: Find the Right Therapy for the Right Patient

Symposia: Aggressive Lymphomas: Clinical and Epidemiological Oral and Poster Abstracts
Oral

Research, clinical trials, Biological therapies, Translational Research, epidemiology, Lymphomas, non-Hodgkin lymphoma, Non-Biological therapies, Clinical Research, health outcomes research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chemotherapy, Combination therapy, Diseases, real-world evidence, aggressive lymphoma, Therapies, Immunotherapy, registries, Lymphoid Malignancies, survivorship, Monoclonal Antibody Therapy

Grand Hall D (Manchester Grand Hyatt San Diego)

Moderators:

Anthony N. Audino, MD, Nationwide Children's Hospital and Alvaro J. Alencar, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine

Disclosures:

Alencar: Amgen: Membership on an entity's Board of Directors or advisory committees; TG Therapeutics: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees, Research Funding; Beigene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees; Epizyme: Membership on an entity's Board of Directors or advisory committees; SeaGen: Membership on an entity's Board of Directors or advisory committees; Lilly: Membership on an entity's Board of Directors or advisory committees, Research Funding; Dr Reddy: Honoraria; Genentech: Membership on an entity's Board of Directors or advisory committees.

This session will cover a wide variety of topics, including the addition of new chemotherapeutic drugs to standard backbone chemotherapy for the treatment of both newly diagnosed and relapsed/refractory aggressive B-Cell Lymphoma; a comparison of HSCT versus CAR-T in Diffuse Large B Cell Lymphoma; the impact of hematopoiesis on clinical outcomes; and whether timing of relapse is a prognostic indicator for Large B Cell Lymphoma.

9:30 AM

439

Early Results Indicate Acceptable Safety and Promising Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

Andrew D. Zelenetz, MD, PhD¹, Catherine S. Diefenbach, MD², Charles Herbaux, MD, PhD³^*, Monica Tani⁴^*, Roch Houot, MD, PhD⁵^*, Mariana Bastos-Oreiro, MD⁶^*, Herve Tilly, MD⁷, Thomas Gastinne, MD⁸^*, Catherine Thieblemont, MD⁹^*, Ethan Troy-Barnes, MBBCh, BAO, MD¹⁰^*, Stefano Olivieri, PhD¹¹^*, Murali Kesavan, MD¹⁰^*, Manisha Kanwar, MDS¹⁰^*, Simona Barlera, MSc¹²^*, Katerina Hatzi, PhD¹³^*, Yanwen Jiang, PhD¹³^*, Michelle Boyer, PhD, BA¹⁰^* and Franck Morschhauser, MD PhD¹⁴

¹Memorial Sloan Kettering Cancer Center, New York, NY
²Perlmutter Cancer Center, NYU Langone Health, New York, NY
³Centre Hospitalier Universitaire de Montpellier, Montpellier, France
⁴Ematologia, Ospedale Santa Maria delle Croci, Ravenna, Italy
⁵Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou, Rennes, France
⁶Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
⁷Centre Henri-Becquerel, Rouen, France
⁸CHU de Nantes, Nantes, France
⁹Hopital Saint-Louis, Paris, France
¹⁰F. Hoffmann-La Roche AG, London, United Kingdom
¹¹F. Hoffmann-La Roche AG, Basel, Switzerland
¹²Parexel International, Milan, Italy
¹³Genentech, Inc., South San Francisco, CA
¹⁴Centre Hospitalier Régional Universitaire de Lille, Lille, France

9:45 AM

440

Addition of High-Dose Methotrexate to Initial Chemotherapy Improved Treatment Outcome of Patients with Newly Diagnosed Intravascular Large B-Cell Lymphoma: A Multicenter, Retrospective Study

Shinpei Harada¹^*, Hideki Goto, MD, PhD²^*, Hajime Senjo, MD³, Keito Suto²^*, Koh Izumiyama⁴^*, Masayo Yamamoto⁵^*, Kazuya Sato⁶, Yasutaka Kakinoki, M.D., Ph.D.⁷^*, Tomoyuki Saga⁸^*, Akio Shigematsu, M.D., Ph.D.⁹, Hiroto Horiguchi, MD, PhD¹⁰, Mutsumi Takahata¹¹^*, Reiki Ogasawara¹²^*, Satoshi Yamamoto, MD, PhD¹³^*, Keisuke Yamaguchi¹⁴^*, Kentaro Wakasa, M.D., Ph.D.¹⁵^*, Tetsuyuki Igarashi, M.D.¹⁶^*, Yoshihito Haseyama¹⁷^*, Shinichi Ito¹⁸^*, Katsuya Fujimoto, M.D., Ph.D.¹⁹^*, Junichi Hashiguchi, M.D.²⁰^*, Masao Nakagawa, MD, PhD², Daigo Hashimoto, MD, PhD²¹ and Takanori Teshima, M.D., Ph.D.²

¹Department of Hematology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo City, Japan
²Department of Hematology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan
³Department of Hematology, Hokkaido University, Kita-Ku, Japan
⁴Blood Disorders Center, Aiiku Hospital, Sapporo, Japan
⁵Division of Metabolism and Biosystemic Science, Gastroenterology and Hematology/Oncology, Asahikawa Medical University, Asahikawa, Japan
⁶Department of Hematology/Oncology, Asahikawa Kosei General Hospital, Asahikawa, Japan
⁷Department of Hematology, Asahikawa City Hospital, Asahikawa, Japan
⁸Department of Hematology, Kin-ikyo Chuo Hospital, Sapporo, Japan
⁹Department of Hematology, Kushiro Rosai Hospital, Kushiro, Japan
¹⁰Department of Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan
¹¹Department of hematology, Sapporo Kosei General Hospital, Sapporo, Japan
¹²Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan
¹³Department of Hematology, Sapporo City General Hospital, Sapporo, Japan
¹⁴Department of Hematology, Teine Keijinkai Medical Center, Sapporo, Japan
¹⁵Department of Hematology, Obihiro Kosei Hospital, Obihiro, Japan
¹⁶Department of Hematology, Tenshi Hospital, Sapporo, Japan
¹⁷Department of Hematology, Tonan Hospital, Sapporo, Japan
¹⁸Department of Hematology, Hakodate Municipal Hospital, Hakodate, Japan
¹⁹Department of Hematology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
²⁰Department of Internal Medicine, Kitami Red Cross Hospital, Kitami, Japan
²¹Hokkaido University Hospital, Sapporo, Japan

10:00 AM

441

Hematopoietic Stem Cell Transplantation for DLBCL: 55,000 Cases from EBMT As a Comparator for CAR T-Cells

Philipp Berning¹^*, Ariane Boumendil²^*, Anthony H. Goldstone³, Anna Maria Sureda Balari, MD, PhD⁴, Peter Dreger, MD⁵, Silvia Montoto, MD⁶, Maud Ngoya²^*, Hervé Finel²^*, Patrice Chevallier, MD⁷, Didier Blaise, MD, PhD⁸, Tim Struessmann, MD⁹^*, Ben Carpenter, MD, PhD¹⁰^*, Edouard Forcade, MD, PhD¹¹^*, Cristina Castilla-Llorente, MD¹²^*, Marek Trněný, MD¹³, Herve Ghesquieres, MD¹⁴^*, Capria Saveria¹⁵^*, Catherine Thieblemont, MD¹⁶^*, Igor Wolfgang Blau, MD, PhD¹⁷^*, Ellen Meijer¹⁸, Annoek E.C. Broers¹⁹^*, Anne Huynh, MD²⁰^*, Denis Caillot, MD²¹^*, Wolf Roesler, MD²²^*, Stéphanie Nguyen Quoc, MD, PhD²³^*, Jörg Bittenbring, MD²⁴^*, Arnon Nagler, MD²⁵, Bertram Glass, MD²⁶^* and Norbert Schmitz¹^*

¹Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
²European Society for Blood and Marrow Transplantation, Paris, France
³HCA Healthcare, Macmillan Cancer Centre, London, GBR
⁴Department of Clinical Hematology, Institut Català d’Oncologia – Hospital Duran I Reynals, IDIBELL, Barcelona, Spain
⁵Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
⁶St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom
⁷CHU de Nantes - Hôtel Dieu, Nantes, France
⁸Program of Transplant and cellular immunotherapy, Department of Hematology, Institut Paoli Calmettes, Marseille, France
⁹Department of Haematology, Oncology and Stem Cell Transplantation, University of Freiburg Medical Center, Freiburg Im Breisgau, Germany
¹⁰University College London Hospitals NHS Foundation Trust, London, United Kingdom
¹¹Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, Pessac, France
¹²Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, France
¹³First Department of Medicine, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic
¹⁴Lyon Sud Hospital, Lyon, France
¹⁵Haematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
¹⁶Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Hemato-oncologie, Université de Paris, Paris, France
¹⁷Department of Hematology, Oncology and Tumor Immunology, Charité Medical University, Berlin, Germany
¹⁸Department of Hematology, VU Medical Center, Amsterdam, Netherlands
¹⁹Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
²⁰Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France
²¹University Hospital INSERM UMR1231 and SAPHIIR-UMR 1231, University of Burgundy & France Comte, Dijon, France
²²Department of Medicine 5, University Hospital of Erlangen, Erlangen, Germany
²³Hematology Department, Sorbonne Université, Hôpital Pitié-Salpêtrière, APHP, Paris, France
²⁴Department of Internal Medicine 1, Oncology, Hematology, Clinical Immunology, and Rheumatology, Saarland University Medical Center, Homburg/Saar, Germany
²⁵Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
²⁶Department of Hematology, HELIOS Klinikum Berlin-Buch, Berlin, Germany

10:15 AM

442

The Impact of Clonal Hematopoiesis on Clinical Outcomes and Clonal Dynamics in Older Lymphoma Patients Receiving Chemotherapy

Rena Buckstein, MD, FRCPC¹, Olivia Lopes, MSc²^*, Amy J. M. McNaughton, PhD³^*, Matthew C. Cheung, MD, MSc⁴, Lee Mozessohn, MD, FRCPC⁵, Lisa Chodirker, MD FRCPC⁶^*, Kevin Imrie, MD, FRCPC⁷, Neil Berinstein, MD, FRCPC⁸, Signy Chow, MD, FRCPC⁹^*, Gillian Kupakuwana-Suk, MD, PhD¹⁰, Anne Parmentier, BA⁹^*, Prasha Sasitharakumar⁹^*, Hubert Tsui, MD, PhD, FRCPC¹¹, Liying Zhang, PhD¹²^* and Michael J. Rauh, MD, PhD³

¹Sunnybrook Odette Cancer Center, Toronto, ON, Canada
²Department of Medicine, University of Ottawa, Ottawa, ON, Canada
³Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada
⁴Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
⁵Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, CAN
⁶Odette Cancer Center, Sunnybrook Health Sciences, University of Toronto, Toronto, ON, Canada
⁷Sunnybrook Health Sciences, Odette Cancer Center, Toronto, ON, CAN
⁸Sunnybrook Health Sciences, Odette Cancer Centre, Toronto, ON, Canada
⁹Sunnybrook Health Sciences, Odette Cancer Center, Toronto, ON, Canada
¹⁰Medicine, Queen's University, Kingston, ON, Canada
¹¹Division of Hematological Pathology, Precision Diagnostics and Therapeutics Program, Sunnybrook Health Science Centre, University of Toronto, Toronto, ON, Canada
¹²MacroStat INC, Toronto, ON, Canada

10:30 AM

443

Post-Transplant Lymphoproliferative Disorders (PTLD) in Real Life: Data from the French K-Virogref Registry on 525 Adult Patients

Antoine Tichadou¹^*, Elise Toussaint²^*, Luc Matthieu Fornecker³^*, Veronique Morel⁴^*, Inès Boussen⁵^*, Damien Roos Weil, MD, PhD⁶^*, Marine Baron⁷^*, Madalina Uzunov, MD⁸^*, Laetitia Souchet⁹^*, Louise Roulin, MD¹⁰^*, Nabih Azar, MD¹¹^*, Stéphane Lepretre¹²^*, Bijou Fontanet¹³^*, Caroline Jacquet, MD¹⁴^*, Eric Durot¹⁵^*, David Boutboul, MD, PhD¹⁶^*, Felipe Suarez, MD, PhD¹⁷, Thomas Cluzeau, M.D.¹⁸^*, Mohamed Touati¹⁹^*, Emmanuel Bachy, MD, PhD²⁰^*, Roch Houot, MD, PhD²¹^*, Fabrice Jardin, MD PhD²²^*, Romain Guieze, MD, PhD²³^*, Loic Ysebaert, MD, PhD²⁴^*, Laure Farnault de Lassus²⁵^* and Sylvain Choquet²⁶^*

¹Assistance Publique HôPitaux De Marseille, Marseille, FRA
²Clinical Hematology, CHU Strasbourg, STRASBOURG, FRA
³Hematology, ICANS, Strasbourg, FRA
⁴Clinical Hematology, Pitie-Salpetriere Hospital, APHP, Sorbonne Universite, Paris Cedex 13, FRA
⁵Clinical Hematology, Pitie-Salpetriere hospital, APHP, Sorbonne Universite, Paris, FRA
⁶Clinical Hematology, APHP, La Pitié Salpétriere, Sorbonne Universite, Paris, FRA
⁷Clinical Hematology, Hôpital Pitié Salpétrière, APHP, Sorbonne Universite, Paris, FRA
⁸Clinical hematology, Pitie-Salpetriere Hopstal, APHP, Sorbonne Universite, Paris, FRA
⁹Pitie Salpetriere Hospital, APHP, Sorbonne Universite, Paris, FRA
¹⁰Henri Mondor Hospital, APHP, Creteil, FRA
¹¹Apheresis, La Pitié Salpétrière Hospital, APHP, Sorbonne Universite, Paris, France
¹²centre henri becquerel, Rouen, FRA
¹³Institut Bergonié, Bordeaux, France
¹⁴CHU de Nancy, Vandoeuvre Les Nancy, FRA
¹⁵CHU Reims, Reims Cedex, France
¹⁶Service d'Immunopathologie Clinique, Saint Louis hospital, AP-HP, Paris, Paris, France
¹⁷Necker Hospital (APHP), Paris, FRA
¹⁸Département d'Hématologie Clinique, Université Cote d'Azur, CHU Nice, Nice, France
¹⁹Hématologie Clinique et Hospitalisation à domicile, CHU Limoges, LIMOGES CEDEX 1, France
²⁰Hematology Department, Lyon Sud Hospital, Pierre-Bénite, France
²¹Clinical hematology, CHU Rennes, Rennes, France
²²Centre Henri Becquerel, Rouen, France
²³CHU Estaing, Clermont Ferrand, FRA
²⁴Hematology Department, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
²⁵Clinical Haematology, CHU Marseille, Marseille, France
²⁶Clinical Hematology, Pitie-Salpetriere hospital, APHP, Sorbonne Universite, Paris, France

10:45 AM

444

Patients with Relapsed Large B-Cell Lymphoma after 12 Months Have a Similarly Poor Prognosis As Patients with a Relapse before 12 Months

Hilde T Van Der Galien^1,2^*, Hilde AM Kooistra, MD, PhD¹^*, Robby Kibbelaar, MD, PhD³^*, Nic JGM Veeger, PhD^4,5^*, Marcel Nijland, MD PhD¹^*, Gerwin A. Huls, Prof.¹, Tom Van Meerten, MD, PhD¹^* and Rozemarijn S Van Rijn, MD, PhD²^*

¹Department of Hematology, University Medical Center Groningen, Groningen, Netherlands
²Department of Hematology, Medical Center Leeuwarden, Leeuwarden, Netherlands
³Pathology Friesland, Leeuwarden, Netherlands
⁴MCL Academy, Medical Center Leeuwarden, Leeuwarden, Netherlands
⁵Department of Epidemiology, University Medical Center Groningen, Groningen, Netherlands

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

627.O3.6 627. Aggressive Lymphomas: Clinical and Epidemiological: Treatment to Best Outcomes: Find the Right Therapy for the Right Patient